
• Reported GAAP EPS of $1.69 down -19.91% YoY • Reported revenue of $60.94B up 11.05% YoY • Cardinal Health raises and narrows fiscal year 2026 non-GAAP diluted EPS guidance to a range of $10.70 to $10.80, reflecting 30% to 31% growth, and adjusted free cash flow to $3.3 billion to $3.7 billion.
Bullish
Cardinal Health saw 11% revenue growth to $60.9 billion and 35% non-GAAP EPS growth, driven by strong segment performance, strategic initiatives, and significant share repurchases.
Bearish
Cardinal Health's GAAP operating earnings and EPS decreased due to a goodwill impairment, while Global Medical Products profit fell 36% due to tariffs and interest expense guidance increased.